title: [ST52 treatment of cancer of the prostate during the hormonal resistance phase].
abstract: OBJECTIVE
  Stilboestrol phosphate (ST 52) was evaluated on pain, general status, life expectancy and PSA, in a retrospective study of patients with prostatic carcinoma and relapse to hormonal treatment.
  
  
  METHODS
  32 patients were treated by infusion of Stilboestrol phosphate at a daily escalating dose from 1.2 to 3 g over a period of 10 days, then subsequently oral administration.
  
  
  RESULTS
  Minor complications, especially nausea were observed in 12 cases but no major complication or interruption of treatment. Improvement for pain alone or with general status was obtained in 50% (16 cases) at 3 months, but at one year only 10% were still improved. Median survival was 8 months, with 19.4 months for responders at the end of infusions and 4.2 months for non-responders-respectively.
  
  
  CONCLUSIONS
  Stilboestrol phosphate can obtain a clinical response with low morbidity when relapse to hormonal treatment occurs. Infusion responders have a better life expectancy.
authors.affiliation: Service d'Urologie, Hôpital Charles Nicolle, Rouen.
authors.forename: P
authors.initials: P
authors.lastname: Grise
authors.forename: A
authors.initials: A
authors.lastname: Mnif
authors.forename: S
authors.initials: S
authors.lastname: Navarra
authors.forename: O
authors.initials: O
authors.lastname: Foulatier
authors.forename: E
authors.initials: E
authors.lastname: Barret
authors.forename: L
authors.initials: L
authors.lastname: Sibert
authors.forename: C
authors.initials: C
authors.lastname: Pfister
mesh_terms: D000284:Administration, Oral; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D004968:Estrogens, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006304:Health Status; D006801:Humans; D007262:Infusions, Intravenous; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010146:Pain / Q000517:prevention & control; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004968:Estrogens, Non-Steroidal; D004054:Diethylstilbestrol; D017430:Prostate-Specific Antigen